|
Abstract | Summary
| Original Article
Combined vitamin B6-magnesium treatment in autism spectrum disorder.
Nye C and Brice A.
(Cochrane Review) In: The Cochrane Library, Issue 1 2003. Oxford: Update Software.
Bottom Line
Do Vitamin B6 and magnesium
supplements improve behaviour
and social and communication
skills in children and adults
with autism?
- Researchers looked at studies that tested whether Vitamin B6 and magnesium supplements improve functioning in people with autism
- They reviewed studies that were designed to see whether the supplements improved use of language or increased the children’s ability to respond to their environment or to other people.
- The studies reviewed were of poor quality and could not answer the questions.
- It is not known if the supplements improve symptoms in children and adults with autism.
|
Question: Do Vitamin B6 and magnesium supplements improve
behaviour and social and communication skills in children and adults
with autism?
Background: In the early 1950s doctors tried using Vitamin
B6 to treat people with schizophrenia. Later studies showed that
there was possible improvement in language use, leading researchers
to try supplements in children with autism. The high doses used
caused side effects such as bedwetting, irritability, and oversensitivity
to sound, but magnesium was added to reduce or eliminate these problems.
Most of the evidence during the early phases of this research was
based on single case reports and not on controlled research. The
purpose of this review was to search published literature to find
reports of rigorous and scientifically valid research on this topic
to demonstrate whether or not Vitamin B6 and magnesium supplements
improve functioning in people with autism.
Data sources: Using a combination of the terms "child-development-disorders-pervasive,"
"speech disorders," "B6," "pyridoxine,"
"magnesium," "vitamin B6", the authors searched
the Cochrane Controlled Trials Register, MEDLINE, EMBASE, and Dissertation
Abstracts International using the FirstSearch search engine and
handsearched the Journal of Autism and Developmental Disabilities.
A further step in the process was to look at the reference lists
of all the articles found and search for missed studies.
Study Selection
Types of Studies: Randomized trials in which one group of
participants was given a combination of Vitamin B6 and magnesium
and a control group was given either a placebo or no treatment.
Types of Participants: Children and adults with a diagnosis
of autism.
Types of Interventions: Combination Vitamin B6 and magnesium
supplementation in either powder or pill form.
Types of Outcome Measures:
1. Verbal behaviour (increased use of language)
2. Non-verbal behaviour (improved ability to respond to environmental
stimuli).
3. Social interaction (increased ability to respond to other people).
Data extraction: Using the inclusion criteria described
above, the authors summarized the findings of the two studies
and commented on the design, participants, interventions and outcomes
found.
Main results: Of the 58 articles found, two studies met
the inclusion criteria and were included in the review. Both of
the studies used a double-blind crossover design. The Tolbert
study did not report the data in a form that could be readily analyzed
and the author was unable to provide further information to make
it so. The Findling study found no significant difference between
the active treatment and placebo conditions.
Conclusions: There is no evidence of an acceptably high
level to state that a combination of Vitamin B6 and magnesium improves
the behaviour or social and communication skills of children and
adults with autism.
The two included studies were:
Findling RL, Maxwell K, Scotese-Wojtila L, Huang J.
High-dose pyridoxine and magnesium administration in children:
An absence of salutary effect in a double-blind, placebo-controlled
study. Journal of Autism and Developmental Disorders 1997; 27(4):
467-78.
Tolbert L, Haigler t, Waits, MM, Dennis T.
Brief report: Lack of response in an autistic population to a low
dose clinical trial of pyridoxine plus magnesium. Journal of Autism
and Developmental Disorders 1993; 23(1): 193-9.
Related articles
Nutritional risks of restricted diets
|
